InVita HemaConnect 2.5 Boosts CGT Donor Recruitment

Houston, Texas, USA – April 23, 2026

InVita Healthcare Technologies and Gulf Coast Blood announced a major advancement in cell and gene therapy (CGT) infrastructure with the release of HemaConnect 2.5, a next-generation donor engagement platform designed to streamline recruitment, scheduling, and tracking of specialized donors for advanced therapies. The enhanced platform introduces tailored workflows and intelligent donor management capabilities, enabling blood centers to support life-saving regenerative medicine, CAR-T therapies, and other cutting-edge treatments with greater efficiency and scale.

Advanced Platform Enhances Donor Recruitment for CGT

The HemaConnect 2.5 release represents a significant evolution in donor engagement technology, specifically addressing the complex requirements of cell and gene therapy donor management. Unlike traditional blood donation workflows, CGT requires highly specialized donor identification, precise scheduling, and detailed tracking of biological samples, all of which are now integrated into the platform.

New features include customized donor profiles tailored to therapy-specific requirements, enabling healthcare providers to capture critical biological and eligibility data necessary for advanced treatments. Additionally, specialized scheduling tools bridge the gap from donor screening to sample collection, ensuring seamless coordination across multiple stages of the donation process.

These enhancements allow blood centers to optimize donor recruitment strategies while maintaining compliance with stringent quality and traceability requirements, which are essential in CGT manufacturing and clinical applications.

Driving Efficiency Across the Cell and Gene Therapy Ecosystem

The collaboration between InVita and Gulf Coast Blood highlights the growing need for integrated digital platforms that support the expanding CGT ecosystem. As demand for therapies such as CAR-T, regenerative medicine, and gene editing treatments continues to rise, efficient donor management has become a critical bottleneck in therapy development and delivery.

HemaConnect 2.5 addresses this challenge by enabling end-to-end coordination of donor engagement, communication, and operational workflows, ensuring that donor recruitment aligns with clinical and manufacturing timelines. The platform also introduces robust administrative capabilities that harmonize traditional blood collection processes with advanced biotherapy requirements, allowing organizations to manage both workflows simultaneously without compromising efficiency or compliance.

By leveraging its extensive network, InVita supports approximately 95% of U.S. blood centers, making this upgrade a scalable solution capable of transforming donor recruitment at a national and global level.

Scaling Digital Infrastructure for Next-Generation Therapies

The launch of HemaConnect 2.5 underscores the increasing role of digital health technologies in enabling precision medicine and advanced therapeutics. With the ability to manage hundreds of millions of donor interactions annually, the platform demonstrates unparalleled scale in donor engagement, including over half a billion emails, 200 million text messages, and millions of scheduled appointments each year.

This scale is critical in supporting the rapid growth of CGT, where timely access to qualified donors directly impacts patient outcomes and therapy success rates. By integrating data-driven insights, automated workflows, and advanced communication tools, HemaConnect 2.5 empowers healthcare organizations to accelerate therapy development while improving patient access to life-saving treatments.

The collaboration also reflects a broader industry trend toward digital transformation in biopharma and healthcare operations, where technology platforms are becoming essential for managing the complexity of modern therapies. As CGT continues to evolve, solutions like HemaConnect 2.5 will play a pivotal role in bridging the gap between donor networks and therapeutic innovation, ultimately enabling more efficient and scalable delivery of advanced treatments.

Source: InVita Healthcare Technologies press release